CA2889110A1 - Methylglyoxal as a marker of cancer - Google Patents

Methylglyoxal as a marker of cancer Download PDF

Info

Publication number
CA2889110A1
CA2889110A1 CA2889110A CA2889110A CA2889110A1 CA 2889110 A1 CA2889110 A1 CA 2889110A1 CA 2889110 A CA2889110 A CA 2889110A CA 2889110 A CA2889110 A CA 2889110A CA 2889110 A1 CA2889110 A1 CA 2889110A1
Authority
CA
Canada
Prior art keywords
cancer
patients
subjects
production level
vitro method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2889110A
Other languages
English (en)
French (fr)
Inventor
Dominique BELPOMME
Philippe IRIGARAY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Association pour la Recherche Therapeutique Anti-Cancereuse
Original Assignee
Association pour la Recherche Therapeutique Anti-Cancereuse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Association pour la Recherche Therapeutique Anti-Cancereuse filed Critical Association pour la Recherche Therapeutique Anti-Cancereuse
Publication of CA2889110A1 publication Critical patent/CA2889110A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
CA2889110A 2012-10-25 2013-10-25 Methylglyoxal as a marker of cancer Abandoned CA2889110A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2012/071163 2012-10-25
PCT/EP2012/071163 WO2014063743A1 (en) 2012-10-25 2012-10-25 Methylglyoxal as a marker of cancer
PCT/EP2013/072459 WO2014064283A1 (en) 2012-10-25 2013-10-25 Methylglyoxal as a marker of cancer

Publications (1)

Publication Number Publication Date
CA2889110A1 true CA2889110A1 (en) 2014-05-01

Family

ID=47074733

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2889110A Abandoned CA2889110A1 (en) 2012-10-25 2013-10-25 Methylglyoxal as a marker of cancer

Country Status (11)

Country Link
US (1) US20150301056A1 (https=)
JP (1) JP6543193B2 (https=)
CN (1) CN104854458B (https=)
CA (1) CA2889110A1 (https=)
DK (1) DK2912465T3 (https=)
ES (1) ES2656896T3 (https=)
MA (1) MA38042B2 (https=)
PT (1) PT2912465T (https=)
RU (1) RU2666255C2 (https=)
TN (1) TN2015000161A1 (https=)
WO (2) WO2014063743A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220206017A1 (en) * 2022-03-18 2022-06-30 Joel Steven Goldberg Aerobic glycolysis and hypermetabolic states

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106769349B (zh) * 2017-01-06 2020-01-21 上海君联医疗设备有限公司 血液中异常糖基化蛋白细胞的检测方法
CN108426996B (zh) * 2017-02-15 2020-09-15 江苏美正生物科技有限公司 一种3-甲基喹噁啉-2-羧酸残留的快速检测试剂盒及其制备方法和应用
GB2566681B (en) * 2017-09-14 2021-07-28 Ip2Ipo Innovations Ltd Biomarker
CN108061802A (zh) * 2017-12-08 2018-05-22 武汉科技大学 一种通过血液检测评定乳腺癌的方法
SG11202104101TA (en) * 2018-11-28 2021-05-28 Nat Univ Singapore Method of detecting cancer and/or tuberculosis
CN110604823B (zh) * 2019-10-21 2020-10-20 兰州大学 一种快速筛选抗糖化和/或抗衰老物质的方法
CN113376199A (zh) * 2021-05-12 2021-09-10 兰立生物科技(苏州)有限公司 一种用于癌症检测的生化分析检测系统
CN114496306B (zh) * 2022-01-28 2022-12-20 北京大学口腔医学院 基于机器学习的预后生存阶段预测方法和系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2007073005A1 (ja) * 2005-12-22 2009-06-04 学校法人慶應義塾 メチル基転移反応調節物質
US8026049B2 (en) * 2007-03-23 2011-09-27 Wisconsin Alumni Research Foundation Noninvasive measurement and identification of biomarkers in disease state
JP4836926B2 (ja) * 2007-11-12 2011-12-14 株式会社日本トリム 糖分解代謝物の測定方法
JP5787339B2 (ja) * 2009-12-28 2015-09-30 学校法人福岡大学 糖尿病前症の検査方法
KR20140024860A (ko) * 2011-02-24 2014-03-03 버밀리언, 인코포레이티드 난소암에 대한 바이오마커 패널，진단 방법 및 시험 키트

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220206017A1 (en) * 2022-03-18 2022-06-30 Joel Steven Goldberg Aerobic glycolysis and hypermetabolic states

Also Published As

Publication number Publication date
CN104854458B (zh) 2018-02-09
JP6543193B2 (ja) 2019-07-10
RU2666255C2 (ru) 2018-09-06
MA38042A3 (fr) 2018-03-30
CN104854458A (zh) 2015-08-19
RU2015119512A (ru) 2016-12-20
US20150301056A1 (en) 2015-10-22
MA38042B2 (fr) 2019-11-29
JP2016500821A (ja) 2016-01-14
DK2912465T3 (en) 2018-01-15
ES2656896T3 (es) 2018-02-28
MA38042A2 (fr) 2017-02-28
WO2014063743A1 (en) 2014-05-01
PT2912465T (pt) 2018-01-25
TN2015000161A1 (en) 2016-10-03
WO2014064283A1 (en) 2014-05-01

Similar Documents

Publication Publication Date Title
DK2912465T3 (en) METHYLGYLOXAL AS A CANCER MARKER
KR101894111B1 (ko) 대상체에서 췌장암을 진단하기 위한 수단 및 방법
Selevsek et al. Systematic quantification of peptides/proteins in urine using selected reaction monitoring
Eisenhofer et al. Biochemical diagnosis of pheochromocytoma
CN106370744A (zh) 8‑羟基脱氧鸟苷作为尿液标志物的应用
EP2894477A1 (en) Method for determining breast cancer
Chen et al. Targeting amine-and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for evaluation of bladder cancer biomarkers
Kałużna-Czaplińska et al. Current applications of chromatographic methods for diagnosis and identification of potential biomarkers in cancer
JP2013246080A (ja) 大腸がん検査方法
US20180164320A1 (en) Method for diagnosis of colorectal cancer using mass spectrometry of n-glycans
Khelfi Immunoassays/ELISA
KR102713301B1 (ko) 췌장암 및 췌장관 내 유두상 점액성 종양의 마커
EP2912465B1 (en) Methylglyoxal as a marker of cancer
CA2705044A1 (en) Methods for detecting or monitoring cancer using lpc as a marker
Deng et al. Nanotrap-enabled quantification of KRAS-induced peptide hydroxylation in blood for cancer early detection
WO2006044680A1 (en) Methods of detecting colorectal cancer
US20140242726A1 (en) LUNG CANCER MARKER COMPLEMENT C3dg MOLECULE, AND METHOD FOR ANALYZING LUNG CANCER MARKER
US20260120870A1 (en) Artificial intelligence-based information provision method for diagnosing lung cancer by using biomarker for lung cancer diagnosis and clinical information of test subject
Ranasinghe et al. Fucosyl monosialoganglioside: Quantitative analysis of specific potential biomarkers of lung cancer in biological matrices using immunocapture extraction/tandem mass spectrometry
KR101803287B1 (ko) 키누레닌 대사 비율 변화를 이용한 위암 진단용 키트
OA17290A (en) Methylglyoxal as marker of cancer.
Lakpour et al. Metabolic fingerprinting of serum and seminal plasma of testicular cancer patients using Raman spectroscopy: a pilot study
KR102884601B1 (ko) 담관암 진단 및 예후 예측용 신규한 바이오마커 및 이의 용도
Xu et al. Simultaneous chiral analysis of DL-asp and DL-α-HB with derivatization in human fingernail by UHPLC-MS/MS: an application in colorectal cancer
Sousa MALDI-TOF MS-based urinary proteomic/peptidomic signature of breast cancer as innovative diagnostic approach

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180913

FZDE Discontinued

Effective date: 20220729